Last edition
News about "Avobis Bio"
Avobis Bio to Present Expanded STOMP2 Trial Data on AVB-114 at ECCO Congress
Expanded STOMP2 trial data highlight sustained safety and efficacy of AVB-114, as Avobis Bio prepares for Phase III development in Crohn’s disease.
Avobis Bio | 30/01/2026 | By News Bureau
Avobis Bio’s lead therapeutic, AVB-114, has received FDA’s RMAT designation for Crohn’s perianal fistulas, building on its Fast Track status to accelerate development with enhanced regulatory support and guidance.
Avobis Bio | 06/10/2025 | By Dineshwori | 253
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy